Eli Lilly and Company (LLY)
| Market Cap | 765.04B |
| Revenue (ttm) | 45.04B |
| Net Income (ttm) | 10.59B |
| Shares Out | 897.57M |
| EPS (ttm) | 11.71 |
| PE Ratio | 72.79 |
| Forward PE | 36.71 |
| Dividend | $6.00 (0.70%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 1,954,939 |
| Open | 870.70 |
| Previous Close | 864.90 |
| Day's Range | 848.05 - 874.92 |
| 52-Week Range | 711.40 - 972.53 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 1,000.53 (+17.39%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,000.53, which is an increase of 17.39% from the latest price.
News
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
INDIANAPOLIS , March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented a...
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approach...
Eli Lilly Shares Rise Over 2% After Key Signal
Eli Lilly & Co. (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
5 Stocks That Could Be The Next Nvidia
Everybody loves a great growth stock. We all know the stories of the incredible wealth delivered by fast-growing companies that keep growing for a long period of time.
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical ...
Novo Nordisk's $2 billion obesity deal
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss Eli Lilly's latest obesity pill trial.
Eli Lilly: Growth With Higher Margins
The Eli Lilly and Company investment thesis highlights a robust 2024 performance, driven by a strong pipeline and solid balance sheet, supporting a positive future outlook. The company's strong cash f...
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
Eli Lilly: A Safe Harbor Amid Market Volatility
My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and st...
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
The Investment Committee debate the latest Calls of the Day.
Final Trades: Visa, Blackstone, Eli Lilly and Invitation Homes
The Investment Committee give you their top stocks to watch for the second half.
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdere...
Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - Head of IR Conference Call Participants Da...
Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday at the Leerink Partn...
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant regrowt...
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcar...
Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of complete skin clearance (EASI 100 or IGA 0) and 87% achieved almost-clear skin (EASI 90) at three years with s...
Big Money Returning for Eli Lilly
Obesity drugs, durable revenue bringing Big Money investors to Eli Lilly and Company (LLY).
The Big 3: AAPL, LLY, AVGO
Dan Deming turns to tech and health care for today's Big 3. He offers example options trades for Apple (AAPL), Eli Lilly (LLY) and Broadcom (AVGO).
US judge denies injunction to stop bar on copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.
Telehealth firms Teladoc, LifeMD tie up with Eli Lilly's pharmacy partner to offer Zepbound
Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer website LillyDirect pharmacy partner, Gifthealth, to offer patients the we...
5 Big Biopharmaceutical Stocks That Are Finding Favor
AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.